KLRB1 and plasma cell myeloma: Therefore, although patients from cluster 2 showed an immune signature associated to a strong cytotoxic response, they also upregulated the expression of inhibitory checkpoints (CD96, LAG3, BTLA, KLRB1) which raised the question of whether this immune signature has an impact in progression to myeloma.